Phase 2 QUINTESSENTIAL Trial Results: GPRC5D-targeted CAR T Showed Significant Overall Response Rate in Relapsed/Refractory Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/phase-2-quintessential-trial-results)

Source URL: https://www.myeloma.org/news-events/multiple-myeloma-news/phase-2-quintessential-trial-results